
    <!DOCTYPE html>
    <html>
    <head>
        <style>
            body { 
                font-family: 'Segoe UI', Roboto, -apple-system, sans-serif; 
                max-width: 1200px; 
                margin: 0 auto; 
                padding: 20px; 
                background-color: #f0f2f5;
                line-height: 1.6;
            }
            .container { 
                background-color: white; 
                padding: 40px; 
                border-radius: 16px; 
                box-shadow: 0 4px 12px rgba(0,0,0,0.1);
            }
            .agent-section { 
                margin-bottom: 35px; 
                padding: 25px; 
                border-radius: 12px; 
                transition: all 0.3s ease;
            }
            .agent-section:hover {
                transform: translateY(-2px);
                box-shadow: 0 4px 15px rgba(0,0,0,0.1);
            }
            .final-annotation { 
                background-color: #f0f7ff; 
                border-left: 5px solid #2196f3; 
            }
            .validator { 
                background-color: #f0fdf4; 
                border-left: 5px solid #22c55e; 
            }
            .formatting { 
                background: linear-gradient(145deg, #fff7ed, #ffe4c4);
                border-left: 5px solid #f97316; 
                box-shadow: 0 4px 15px rgba(249, 115, 22, 0.1);
            }
            h2 { 
                color: #1a2b3c; 
                margin-top: 0; 
                font-size: 1.5rem;
                font-weight: 600;
                display: flex;
                align-items: center;
                gap: 10px;
            }
            ul { 
                margin: 15px 0; 
                padding-left: 20px; 
            }
            pre { 
                background-color: #f8fafc; 
                padding: 20px; 
                border-radius: 8px; 
                overflow-x: auto;
                font-family: 'Consolas', 'Monaco', monospace;
                font-size: 0.9rem;
                line-height: 1.5;
            }
            .validation-result { 
                font-weight: 600; 
                color: #16a34a; 
                padding: 12px 20px;
                background-color: #dcfce7; 
                border-radius: 8px; 
                display: inline-block;
                margin: 10px 0;
            }
            br { 
                margin-bottom: 8px; 
            }
            p {
                margin: 12px 0;
                color: #374151;
            }
            .summary-content {
                display: flex;
                flex-direction: column;
                gap: 24px;
            }
            .summary-item {
                display: flex;
                flex-direction: column;
                gap: 8px;
                background: rgba(255, 255, 255, 0.7);
                padding: 16px;
                border-radius: 12px;
                backdrop-filter: blur(8px);
                box-shadow: 0 2px 8px rgba(0, 0, 0, 0.05);
            }
            .summary-label {
                font-weight: 600;
                color: #c2410c;
                font-size: 0.95rem;
                text-transform: uppercase;
                letter-spacing: 0.5px;
            }
            .summary-value {
                color: #1f2937;
                font-size: 1.1rem;
                padding: 8px 16px;
                background-color: rgba(255, 255, 255, 0.9);
                border-radius: 8px;
                display: inline-block;
                box-shadow: 0 1px 3px rgba(0, 0, 0, 0.1);
            }
            .summary-list {
                margin: 0;
                padding-left: 24px;
                list-style-type: none;
            }
            .summary-list li {
                color: #1f2937;
                padding: 8px 0;
                position: relative;
            }
            .summary-list li:before {
                content: "‚Ä¢";
                color: #f97316;
                font-weight: bold;
                position: absolute;
                left: -20px;
            }
            .report-header {
                text-align: center;
                margin-bottom: 40px;
                padding-bottom: 30px;
                border-bottom: 2px solid rgba(249, 115, 22, 0.2);
            }
            
            .report-title {
                font-size: 2.5rem;
                font-weight: 800;
                color: #1a2b3c;
                margin: 0;
                padding: 0;
                background: linear-gradient(135deg, #f97316, #c2410c);
                -webkit-background-clip: text;
                -webkit-text-fill-color: transparent;
                letter-spacing: -0.5px;
            }
            
            .report-subtitle {
                font-size: 1.1rem;
                color: #64748b;
                margin-top: 8px;
                font-weight: 500;
            }
            .scoring { 
                background: linear-gradient(145deg, #f0fdf4, #dcfce7);
                border-left: 5px solid #22c55e;
                box-shadow: 0 4px 15px rgba(34, 197, 94, 0.1);
            }
            .scoring-content {
                display: flex;
                flex-direction: column;
                gap: 16px;
                color: #1f2937;
                line-height: 1.8;
            }
            .scoring-content br + br {
                content: "";
                display: block;
                margin: 12px 0;
            }
            .empty-list {
                color: #6b7280;
                font-style: italic;
            }
            .error-message {
                color: #dc2626;
                padding: 12px;
                background-color: #fef2f2;
                border-radius: 6px;
                border-left: 4px solid #dc2626;
            }
            .score-badge {
                background: linear-gradient(135deg, #22c55e, #16a34a);
                color: white;
                padding: 8px 16px;
                border-radius: 12px;
                font-size: 1.5rem;
                font-weight: 700;
                display: inline-block;
                margin: 12px 0;
                box-shadow: 0 4px 12px rgba(34, 197, 94, 0.2);
                position: relative;
                top: -10px;
            }
            .score-badge::before {
                content: "Score:";
                font-size: 0.9rem;
                font-weight: 500;
                margin-right: 8px;
                opacity: 0.9;
            }
        </style>
    </head>
    <body>
        <div class="container">
            <div class="report-header">
                <h1 class="report-title">CASSIA Analysis Report</h1>
                <p class="report-subtitle">Comprehensive Cell Type Analysis and Annotation</p>
            </div>
            
                <div class="agent-section final-annotation">
                    <h2>üîç Final Annotation Analysis</h2>
                    To annotate the cell type based on the provided ranked marker list from a single-cell human dataset derived from breast cancer tissue, we will follow the outlined steps:<br><br>### Step 1: List the Key Functional Markers<br>- **TRAC, TRBC2, TRBC1, CD3D, CD3G, CD3E, CD247**: These are components of the T-cell receptor (TCR) complex, crucial for antigen recognition and T-cell activation.<br>- **GZMA, NKG7, CCL5**: These are associated with cytotoxic functions. Granzyme A (GZMA) is involved in inducing apoptosis in target cells, NKG7 is linked to cytotoxic granule exocytosis, and CCL5 is a chemokine involved in recruiting immune cells.<br>- **LCK, FYN**: These are Src family kinases involved in TCR signaling.<br>- **IL32, IL7R, IL2RG**: These are cytokines and cytokine receptors involved in T-cell proliferation and survival.<br>- **PTPRC (CD45)**: A protein tyrosine phosphatase involved in TCR signaling.<br>- **RAC2, CORO1A**: Involved in actin cytoskeleton organization, important for cell movement and immune synapse formation.<br><br>### Step 2: List the Key Cell Type Markers<br>- **CD3D, CD3E, CD3G, CD247**: These are definitive markers for T-cells, as they are part of the TCR complex.<br>- **CD2, CD7, CD27, CD96, CD69**: These are surface markers commonly found on T-cells, with CD69 being an early activation marker.<br>- **TIGIT, LTB, CXCR4**: These are markers associated with T-cell subsets, including regulatory and memory T-cells.<br>- **PTPRC (CD45)**: A common leukocyte antigen, present on all hematopoietic cells except erythrocytes.<br><br>### Step 3: Cross-reference Known Databases<br>Using databases such as the Human Cell Atlas, PanglaoDB, and literature on T-cell markers, the presence of CD3 complex components, CD2, CD7, and other T-cell specific markers strongly suggests a T-cell identity. The expression of cytotoxic markers like GZMA and NKG7 further supports a cytotoxic T-cell phenotype.<br><br>### Step 4: Determine the Most Probable General Cell Type<br>Based on the expression of the TCR complex, CD3, CD2, and other T-cell specific markers, the most probable general cell type is a **T-cell**.<br><br>### Step 5: Identify the Top 3 Most Probable Sub Cell Types<br>1. **Cytotoxic T Lymphocytes (CTLs)**: The presence of GZMA, NKG7, and CCL5 suggests a cytotoxic function, typical of CTLs.<br>2. **Effector Memory T-cells**: The expression of CD69, IL7R, and CXCR4 indicates an activated or memory phenotype.<br>3. **Regulatory T-cells (Tregs)**: Although less likely due to the lack of FOXP3, the presence of TIGIT and CD27 could suggest a regulatory role.<br><br>The most likely subtype, given the strong expression of cytotoxic markers, is **Cytotoxic T Lymphocytes (CTLs)**.<br><br>### Step 6: Provide a Concise Summary of Your Analysis<br>The ranked marker list from the breast cancer tissue dataset indicates a T-cell identity, with a strong likelihood of being cytotoxic T lymphocytes (CTLs) due to the expression of TCR components, cytotoxic markers (GZMA, NKG7), and activation markers (CD69). The presence of these markers aligns with known profiles of CTLs, which play a crucial role in immune surveillance and tumor cell killing.<br><br>**FINAL ANNOTATION COMPLETED**
                </div>
            
                <div class="agent-section validator">
                    <h2>‚úì Validation Check</h2>
                    <div class="validation-result">‚úÖ VALIDATION PASSED</div>
                    Validation result: VALIDATION PASSED<br><br>The proposed annotation result is consistent with the provided marker list and the identified cell type. Here's the breakdown:<br><br>1. **Marker Consistency**:<br>   - The markers used in the annotation (e.g., TRAC, CD3D, CD3E, CD3G, CD247, GZMA, NKG7, CCL5, LCK, PTPRC, IL7R, IL2RG, RAC2, CORO1A) are present in the provided marker list.<br>   - The markers are consistent with a T-cell identity, particularly cytotoxic T lymphocytes (CTLs), as they include components of the T-cell receptor complex, cytotoxic markers, and activation markers.<br><br>2. **Mixed Cell Type Consideration**:<br>   - The annotation considers potential subtypes within the T-cell population, such as cytotoxic T lymphocytes, effector memory T-cells, and regulatory T-cells.<br>   - The strong expression of cytotoxic markers (GZMA, NKG7) supports the primary annotation of CTLs, while the presence of other markers (e.g., CD69, TIGIT) suggests possible subpopulations, which is appropriately flagged for further investigation.<br><br>Overall, the annotation aligns well with the marker list and known profiles of T-cell subtypes, particularly CTLs, in the context of breast cancer tissue.
                </div>
            
                        <div class="agent-section formatting">
                            <h2>üìã Summary</h2>
                            
                        <div class="summary-content">
                            <div class="summary-item">
                                <span class="summary-label">Main Cell Type:</span>
                                <span class="summary-value">T-cell</span>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Sub Cell Types:</span>
                                <ul class="summary-list">
                                    <li>Cytotoxic T Lymphocytes (CTLs)</li><li>Effector Memory T-cells</li><li>Regulatory T-cells (Tregs)</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Possible Mixed Cell Types:</span>
                                <ul class="summary-list">
                                    <li class="empty-list">No mixed cell types identified</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Number of Markers:</span>
                                <span class="summary-value">50</span>
                            </div>
                        </div>
                    
                        </div>
                    
                    <div class="agent-section scoring">
                        <h2>üéØ Quality Assessment</h2>
                        <div class="score-badge">90</div>
                        <div class="scoring-content">
                            The annotation results provided demonstrate a strong understanding of the marker list and its implications for identifying cell types within the dataset. The analysis correctly identifies the main cell type as T-cells, which is supported by the presence of key T-cell receptor components such as TRAC, CD3D, CD3E, CD3G, and CD247. The identification of Cytotoxic T Lymphocytes (CTLs) as the primary subtype is well-justified by the presence of cytotoxic markers like GZMA and NKG7, which are crucial for the cytotoxic function of these cells.<br><br>The annotation also considers other potential T-cell subtypes, such as Effector Memory T-cells and Regulatory T-cells, which demonstrates a balanced approach to the data. This consideration of multiple subtypes is important for capturing the complexity of the cell populations present in the breast cancer tissue.<br><br>The analysis effectively uses a wide range of markers, rather than over-focusing on a single marker, which is a strength. The inclusion of activation markers (e.g., CD69) and cytokine receptors (e.g., IL7R, IL2RG) further supports the identification of T-cell subtypes and their functional states.<br><br>However, there are a few areas where the analysis could be improved. While the annotation does consider the rank of the markers, it could place more emphasis on the most highly ranked markers to ensure that the most critical markers are given appropriate weight in the analysis. Additionally, the annotation could benefit from a more explicit discussion of the potential for mixed cell types, even if they are deemed unlikely, to ensure a comprehensive view of the data.<br><br>Overall, the annotation is scientifically accurate, well-balanced, and provides a comprehensive view of the cell types present, with only minor areas for improvement.<br>
                        </div>
                    </div>
                
        </div>
    </body>
    </html>
    